Browse articles from EyeWorld.org related to myopia. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Positive topline data from Phase 3 study for thyroid eye disease treatment ➤ Controlled U.S. release of outflow restoration platform for glaucoma ➤ New platform established to help bring supportive evidence to interventional glaucoma ➤ Head-to-head Phase 1b study supports investigational anti-VEGF ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ 24-month pivotal data support efficacy of laser treatment for glaucoma ➤ Low-dose atropine drop meets primary, secondary endpoints in new data analysis ➤ Phase 2 topline data for modifier gene therapy for geographic atrophy ➤ Phase 2 data from study evaluating neuropathic corneal pain shows quality of life improvement ➤ New shelf-stable corneal endothelial cell therapy program begins ➤ ASCRS news and events
➤ Positive results in Phase 3 superiority trial for wet AMD treatment ➤ Dosing begins for first-in-human myopia prevention drop ➤ Pre-NDA meeting with FDA for IOP-lowering drop ➤ Company news ➤ ASCRS news and events
➤ Topline Phase 3 results for low-dose atropine drop ➤ 12-month data from prospective pilot study assessing aqueous shunt ➤ 5-year follow-up data supports safety, tolerability of investigational retinitis pigmentosa treatment. ➤ Randomization achieved in registrational trial for wet AMD therapy ➤ BLA submitted for thyroid eye disease treatment ➤ Company news ➤ ASCRS news and events
➤ Complete response letter issued for low-dose atropine drop ➤ Extension study shows reduced GA growth with intravitreal treatment ➤ Durable, 3-year vision improvements seen with optogenetic therapy ➤ Preclinical data supports long-acting nature of investigational anti-VEGF for wet AMD ➤ Company news ➤ ASCRS news and events
➤ Phase 3 results for preservative-free redness reliever ➤ Enrollment complete in Phase 3 pivotal program for wet AMD treatment ➤ Dry AMD Phase 3 trial completes enrollment ➤ Study: 24-month data confirm durability of dry eye procedural treatment ➤ Partnership and acquisition news ➤ ASCRS news and events
➤ Topline Phase 2 results for drug treating neuropathic corneal pain ➤ Phase 3 blepharitis treatment doesn’t meet primary endpoint ➤ Study: therapeutic potential of collagen mimetic peptides for myopia ➤ FDA accepts NDA resubmission for dry eye therapy ➤ Partnership news ➤ ASCRS news and events
Progressive pediatric myopia, its increasing prevalence, and possible treatments are important topics for eyecare providers, even if their primary patient population isn’t pediatric. One pediatric ophthalmologist said it’s important to understand the research that’s going on in this area because it affects a large percentage of the population globally.
➤ Long-term data on treatment for neuropathic corneal pain ➤ European agency issues positive opinion for low-dose atropine formulation ➤ Study: semaglutide use associated with increased risk of NAION ➤ Company news ➤ ASCRS news and events